| 2.6 1.2 (85.71%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.21 |
1-year : | 3.75 |
| Resists | First : | 2.75 |
Second : | 3.21 |
| Pivot price | 1.49 |
|||
| Supports | First : | 1.9 |
Second : | 1.37 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.48 |
| MA(100) : | 1.31 |
MA(250) : | 1.24 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.6 |
D(3) : | 32 |
| RSI | RSI(14): 88.9 |
|||
| 52-week | High : | 2.75 | Low : | 0.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BOLD ] has closed It is unclear right now based on current values. 396.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.75 - 2.77 | 2.77 - 2.78 |
| Low: | 2.22 - 2.24 | 2.24 - 2.25 |
| Close: | 2.58 - 2.6 | 2.6 - 2.62 |
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Tue, 23 Jun 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) - PR Newswire
Tue, 23 Jun 2026
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Tue, 23 Jun 2026
Boundless Bio Inc. (BOLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Tue, 23 Jun 2026
BOLD Stock Pops As Traders Target Volatile Bounce - StocksToTrade
Tue, 23 Jun 2026
BOLD: All-stock merger creates a focused gene editing company targeting AATD with strong financial runway - TradingView
Tue, 23 Jun 2026
BOLD: All-stock merger creates a gene-editing leader targeting AATD, with Boundless shareholders receiving a cash dividend - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 49.7 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | -2.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|